Melbourne, Australia, 20 October 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
This year’s AusBiotech Convention will be attended by OccuRx’s Chief Operating Officer, Dr Michelle Bradney.
AusBiotech is scheduled to take place 26 – 28 October 2022 in Perth, Western Australia and will enable OccuRx to connect with over 3,000 members in the life sciences.
The OccuRx team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including their clinical development progress and plans with its novel therapeutic platform.
OccuRx has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis. These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, eye, and skin. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally. OccuRx is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment
The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
Come and meet with us in person to discuss our broad clinical research pipeline focused on precision therapies for chronic and rare kidney diseases.
Or please email us at email@example.com